Last updated: July 31, 2026
HYZAAR is a fixed-dose combination of losartan potassium and hydrochlorothiazide used to treat hypertension. Its commercial opportunity is concentrated in generic substitution, formulation differentiation, contract manufacturing, private-label supply, and global regulatory filings rather than in new-chemical-entity exclusivity. The most practical excipient strategy is a robust immediate-release tablet platform that controls hydrochlorothiazide content uniformity, protects losartan stability, supports multiple strengths, and avoids unnecessary formulation complexity.
What is HYZAAR and how is it formulated?
HYZAAR contains losartan potassium, an angiotensin II receptor blocker, and hydrochlorothiazide, a thiazide diuretic. In the United States, the marketed strengths are:
| Strength |
Losartan potassium |
Hydrochlorothiazide |
Dosage form |
| HYZAAR 50/12.5 mg |
50 mg |
12.5 mg |
Film-coated tablet |
| HYZAAR 100/12.5 mg |
100 mg |
12.5 mg |
Film-coated tablet |
| HYZAAR 100/25 mg |
100 mg |
25 mg |
Film-coated tablet |
The product is an immediate-release oral tablet. The reference formulation uses conventional pharmaceutical excipients, including lactose monohydrate, microcrystalline cellulose, pregelatinized starch, magnesium stearate, and coating materials such as hypromellose, hydroxypropyl cellulose, titanium dioxide, and carnauba wax, according to the FDA prescribing information and DailyMed product record.[1,2]
The formulation challenge is not the total drug load. It is the need to distribute a relatively low hydrochlorothiazide dose uniformly through a tablet containing a substantially larger amount of losartan potassium and excipients. Hydrochlorothiazide represents 12.5% of the active-drug mass in the 50/12.5-mg strength and 11.1% in the 100/12.5-mg strength.
What excipient strategy is appropriate for losartan potassium and hydrochlorothiazide?
A direct-compression or dry-granulation platform is commercially attractive because it limits process steps, reduces water exposure, and can support several strengths using a common blend architecture. The final choice depends on powder flow, segregation tendency, tablet tensile strength, dissolution performance, and stability data.
Diluent and compression system
Microcrystalline cellulose is a logical principal filler and dry binder. It improves compactibility and can compensate for the limited binding contribution of the active ingredients. Lactose monohydrate can increase bulk and improve tablet processing, but the lactose grade must be selected for flow, particle-size distribution, and compatibility.
A lactose-free formulation can replace lactose with mannitol, dibasic calcium phosphate, or a combination of microcrystalline cellulose and coprocessed excipients. Each option changes tablet density, hardness, friability, dissolution, and cost. Dibasic calcium phosphate may improve flow and reduce hygroscopicity, but its higher density can increase segregation risk and alter dissolution behavior.
Disintegrant selection
Pregelled starch is consistent with an immediate-release tablet design. Crospovidone, croscarmellose sodium, and sodium starch glycolate are alternative disintegrants. Crospovidone is useful where rapid water uptake and low gelling risk are priorities. Croscarmellose sodium can produce strong disintegration at low concentrations but requires control of swelling and blend uniformity.
The disintegrant should be evaluated in both intragranular and extragranular locations if granulation is used. For direct compression, an extragranular high-efficiency disintegrant may be sufficient, provided that tablet hardness does not delay dissolution.
Lubricant and glidant controls
Magnesium stearate is a standard lubricant for the platform. Excessive blending can create hydrophobic particle coatings, reduce tablet tensile strength, and slow dissolution. Lubricant concentration and blending time should therefore be treated as critical process parameters.
Colloidal silicon dioxide may improve flow in a direct-compression formulation. Its use should be balanced against increased dusting, electrostatic behavior, and possible effects on blend uniformity.
Film-coating system
A conventional hypromellose film coat can provide color differentiation among strengths, improve swallowability, and reduce handling dust. Titanium dioxide and iron oxides may be used for opacity and strength identification, subject to jurisdiction-specific excipient requirements.
A branded or private-label product can differentiate through a low-weight, pigment-free, or moisture-protective coating. Coating changes should not compromise dissolution, tablet identification, or stability.
What formulation risks affect commercial development?
The principal technical risks are blend segregation, low-dose hydrochlorothiazide uniformity, losartan degradation, dissolution variability, and scale-up behavior.
| Risk |
Commercial effect |
Mitigation |
| Hydrochlorothiazide segregation |
Content-uniformity failures and batch rejection |
Particle-size matching, ordered blending, granulation, in-process sampling |
| Over-lubrication |
Slower dissolution and weaker tablets |
Defined magnesium stearate concentration and blend endpoint |
| Moisture exposure |
Stability loss or altered compression behavior |
Low-moisture excipients, controlled humidity, protective packaging |
| Strength changes |
Separate process validation burden |
Platform formulation with controlled drug-to-excipient ratios |
| Coating variability |
Appearance complaints and identification errors |
Automated spray control and validated weight gain |
| Poor powder flow |
Weight variation and low throughput |
Glidant optimization, roller compaction, or dry granulation |
Losartan potassium is generally handled as a conventional solid oral active, but the development program should assess moisture, particle-size distribution, polymorphic behavior, and interaction with excipients. Hydrochlorothiazide has low dose strength in the combination and requires a validated analytical method capable of resolving both actives and relevant degradation products.
What patents protect HYZAAR and when does HYZAAR lose exclusivity?
The original losartan and losartan/hydrochlorothiazide exclusivity periods have expired in the United States. HYZAAR is a mature product with established generic competition. FDA Orange Book information should be checked by product and applicant because listing status, patent delisting, and historical entries can change over time.[3]
The commercial estate is primarily exposed to:
- Formulation and process patents, if still enforceable in a particular jurisdiction.
- Method-of-use patents covering hypertension or cardiovascular risk reduction.
- Manufacturing patents directed to losartan potassium, hydrochlorothiazide, intermediates, or tablet processing.
- Regulatory exclusivity linked to a specific generic approval, where applicable.
The original active-ingredient patent estate is no longer the principal barrier to U.S. generic entry. A new entrant should conduct a current patent search across the United States, Europe, Canada, Japan, and major emerging markets because geographic protection and regulatory pathways are not synchronized.
What is the Orange Book status of HYZAAR?
HYZAAR is an FDA-approved immediate-release fixed-dose combination product. FDA Orange Book records identify approved reference products and therapeutically equivalent generic products. Generic losartan potassium/hydrochlorothiazide tablets have been approved through abbreviated new drug applications, subject to the applicable reference-product and bioequivalence requirements.[3,4]
For a generic sponsor, the regulatory strategy is usually an ANDA rather than a 505(b)(2) application. The application must demonstrate pharmaceutical equivalence and bioequivalence to the reference product and comply with current good manufacturing practice requirements.
A reformulated product using a different excipient system may still qualify for an ANDA if it meets the applicable sameness and performance requirements. A materially different dosage form, release profile, or clinical positioning could require a different regulatory pathway.
Which companies are challenging or competing with HYZAAR?
Competition comes from three groups:
- Generic manufacturers selling losartan/hydrochlorothiazide tablets.
- Suppliers of the individual components, including losartan potassium and hydrochlorothiazide.
- Competing fixed-dose antihypertensive combinations, such as valsartan/hydrochlorothiazide, irbesartan/hydrochlorothiazide, and olmesartan/hydrochlorothiazide.
The key competitive variable in the U.S. is usually price and supply reliability. In lower-volume or fragmented international markets, tablet appearance, pack size, registration support, local manufacturing, and distributor access can matter as much as unit price.
What commercial opportunities exist for excipient suppliers?
Excipient suppliers have several opportunities around the HYZAAR platform.
Low-segregation formulation systems
Coprocessed excipients combining filler, binder, and disintegrant functionality can reduce development time and improve direct-compression performance. The value proposition is strongest for manufacturers seeking a common platform across 50/12.5, 100/12.5, and 100/25 mg strengths.
Lactose-free and low-moisture formulations
A lactose-free option can address manufacturing preferences, patient-labeling requirements, or market-specific restrictions. Mannitol- or cellulose-based systems may provide a differentiated product without changing the active ingredients.
Film-coating systems
Ready-to-use coating premixes can reduce color-matching work, simplify scale-up, and support strength differentiation. Moisture-protective coating systems may be relevant where packaging conditions are less controlled.
Continuous manufacturing and process analytical technology
Losartan/hydrochlorothiazide is suitable for development of continuous blending, tablet compression, and real-time dose-uniformity control. The commercial benefit is lower material hold-up, tighter process control, and potentially lower batch-to-batch variability.
Packaging and stability support
Blister systems, high-barrier bottles, desiccants, and moisture-resistant coatings can support distribution in hot and humid climates. Packaging suppliers can compete by offering stability data tied to the specific formulation and market.
How strong is the formulation patent estate?
The formulation patent position is weaker than the original active-ingredient estate because the product is mature and multiple generic formulations are commercially established. A new formulation patent would need a defensible claim covering a specific composition, process, stability advantage, dissolution profile, or manufacturing result.
A broad claim covering losartan, hydrochlorothiazide, and ordinary tablet excipients would face substantial validity and freedom-to-operate risk. More defensible opportunities may involve:
- A demonstrated low-segregation blend architecture.
- A specific excipient ratio that improves hydrochlorothiazide uniformity.
- A moisture-protective composition with unexpected stability results.
- A process that produces equivalent dissolution with reduced manufacturing complexity.
- A novel multiparticulate or modified-release system supported by clinical or pharmacokinetic data.
Patent value depends on whether the claim can block a commercially meaningful alternative. A narrow excipient patent may have limited value if generic manufacturers can redesign the blend without affecting approval or product performance.
What generic launch opportunities exist?
The strongest opportunity is a reliable, low-cost immediate-release tablet with three strengths and minimal formulation complexity. A launch program should prioritize:
- Common excipient platform across all strengths.
- Robust hydrochlorothiazide content uniformity.
- Rapid, reproducible dissolution.
- Stable supply of losartan potassium and hydrochlorothiazide.
- Packaging suitable for multiple climate zones.
- Flexible tablet tooling and color coding.
- Regulatory dossiers that support multiple countries.
A differentiated launch may use a lactose-free formulation, an orally disintegrating tablet, a smaller tablet, or a combination pack. These approaches can create commercial distinction but may increase regulatory, stability, and manufacturing costs.
An orally disintegrating HYZAAR product would require careful assessment of taste, mechanical strength, dose uniformity, and whether the target patient population would pay for or receive a meaningful benefit. A smaller tablet may be more commercially practical if achieved through high-density excipients and optimized compression.
What litigation and settlement issues affect HYZAAR?
The principal historical litigation risk involved the original losartan and combination-product patent estate. With the core U.S. exclusivity period expired, current commercial risk is more likely to involve:
- ANDA certification disputes.
- Manufacturing or supplier patent claims.
- Product liability and labeling claims.
- Quality failures or recalls.
- Antitrust allegations involving generic supply or distribution.
- Contract disputes between licensees, API suppliers, and finished-dose manufacturers.
Settlement agreements can affect launch timing when a listed patent remains relevant, but the impact must be assessed from current Orange Book entries, court dockets, and the specific ANDA certification. Historical litigation involving the reference product should not be treated as a current launch barrier without confirming the live patent and regulatory record.
How does HYZAAR compare with competing fixed-dose combinations?
| Product class |
Active ingredients |
Excipient opportunity |
Competitive position |
| HYZAAR |
Losartan plus hydrochlorothiazide |
Low-dose uniformity and common-platform tablets |
Mature generic market |
| Valsartan/hydrochlorothiazide |
Valsartan plus hydrochlorothiazide |
Similar immediate-release platform |
Strong ARB combination competitor |
| Irbesartan/hydrochlorothiazide |
Irbesartan plus hydrochlorothiazide |
Flow, compression, and tablet-size optimization |
Mature generic market |
| Olmesartan/hydrochlorothiazide |
Olmesartan plus hydrochlorothiazide |
Stability and high-quality coating systems |
Differentiation through supply and packaging |
HYZAAR’s commercial advantage is recognition and long clinical use. Its weakness is limited product differentiation after generic entry. Excipient innovation must therefore produce a measurable manufacturing, stability, regulatory, or patient-use advantage.
Key Takeaways
- HYZAAR is a mature losartan potassium/hydrochlorothiazide fixed-dose combination with expired core U.S. exclusivity.
- The principal formulation issue is low-dose hydrochlorothiazide distribution within a losartan-containing tablet.
- Microcrystalline cellulose, lactose or lactose-free fillers, pregelatinized starch, magnesium stearate, and conventional film coatings support a practical immediate-release platform.
- Direct compression and dry granulation are the leading development approaches.
- The strongest commercial opportunities are generic supply, private-label manufacturing, excipient platforms, lactose-free formulations, high-barrier packaging, and international registration.
- A new patent is more likely to be defensible around a demonstrated process or composition advantage than around ordinary excipient substitution.
- Current Orange Book entries, patent listings, ANDA certifications, and litigation dockets should control any launch or freedom-to-operate decision.
FAQs
Is HYZAAR still protected by patents?
The original U.S. patent and exclusivity protection for losartan and HYZAAR has expired. Current jurisdiction-specific patent listings must be reviewed before launch.
What excipients are used in HYZAAR tablets?
The reference product uses lactose monohydrate, microcrystalline cellulose, pregelatinized starch, magnesium stearate, and film-coating materials, according to FDA labeling and DailyMed.[1,2]
Can a generic HYZAAR use different excipients?
Yes. An ANDA product may use different inactive ingredients if it satisfies applicable FDA requirements for pharmaceutical equivalence, safety, bioequivalence, dissolution, and labeling.[4]
Is there a commercial opportunity for a lactose-free HYZAAR?
Yes. A lactose-free tablet can support differentiated manufacturing and labeling, but it must maintain content uniformity, dissolution, stability, and bioequivalence.
Is HYZAAR suitable for a new formulation patent?
Potentially, but ordinary excipient substitutions are unlikely to create a strong exclusionary position. A patent case is stronger when the formulation demonstrates an unexpected stability, uniformity, dissolution, compression, or manufacturing benefit.
References
- U.S. Food and Drug Administration. (2023). HYZAAR (losartan potassium and hydrochlorothiazide) tablets: Prescribing information.
- National Library of Medicine. (2024). DailyMed: HYZAAR- losartan potassium and hydrochlorothiazide tablet, film coated.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- U.S. Food and Drug Administration. (2017). Size, shape, and other physical attributes of generic tablets and capsules: Guidance for industry.
